FDA Links 15 Infections To Texas Compounding Pharmacy

Law360, New York (August 9, 2013, 5:12 PM EDT) -- The U.S. Food and Drug Administration on Friday said it suspects at least 15 patients were sickened by a Texas compounding pharmacy’s product, the latest outbreak to harm the field’s image and drive Congress to consider enacting stricter oversight.

Austin-area Specialty Compounding produced calcium gluconate infusions and sold them to a pair of hospitals for use in patients who later developed bacterial bloodstream infections, the FDA said.

Samples of calcium gluconate made by Specialty Compounding “show growth of bacteria that are consistent” with the Rhodococcus equi...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.